1048 GMT - AstraZeneca stands out among peers with its diversified pipeline of new experimental drugs and extensions for on-market assets, UBS analysts say in a note. "Clearly some studies will fail, but 2025 is a key catalyst year with data on seven high-value new drugs," they say. Its new small-cell lung and bladder indications for cancer drug Imfinzi and its late stage trials to broaden the label of pulmonary disease treatment Breztri are promising, they say. UBS analysts estimate that the British pharma company's late-stage pipeline has potential to add a further $17.6 billion sales in 2030. UBS upgrades its rating on the stock to buy from neutral. Shares are up 1.7% at 120.00 pounds. (helena.smolak@wsj.com)
(END) Dow Jones Newswires
February 13, 2025 05:49 ET (10:49 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。